Table 1.
Distribution of baseline prostate-specific antigen (PSA) level by age at baseline for the Krimpen study, the Scandinavian Prostatic Cancer Group 4 (SPCG-4) cohort, and the UK cohort, showing median and interquartile range (IQR)
| Krimpen study | SPCG-4 cohort | UK cohort | ||||
|---|---|---|---|---|---|---|
| Age group, yr |
PSA median, ng/ml (IQR) |
n (%) | PSA median, ng/ml (IQR) |
n (%) | PSA median, ng/ml (IQR) |
n (%) |
| <50 | 1.1 (0.6–1.6) |
8 ( 0.2) |
– | 0 | 3.8 (1.7–4.1) |
3 ( 0.9) |
| 51–55 | 0.9 (0.6–1.3) |
309 ( 9.5) |
9.7 (4.2–20.6) |
8 ( 2.5) |
4.2 (3.4–6.2) |
39 (12.2) |
| 56–60 | 1.0 (0.6–1.7) |
377 (19.6) |
12.0 (5.8–18.3) |
44 (13.7) |
4.9 (3.5–7.0) |
68 (21.3) |
| 61–65 | 1.1 (0.7–2.1) |
351 (20.0) |
8.9 (5.2–15.5) |
95 (29.6) |
4.9 (3.5–7.0) |
116 (36.3) |
| 66–70 | 1.4 (0.8–2.5) |
266 (15.5) |
8.8 (5.7–16.0) |
117 (36.4) |
5.1 (3.7–6.9) |
93 (29.1) |
| >70 | 1.8 (1.0–3.4) |
151 (35.1) |
9.2 (5.8–16.3) |
57 (17.8) |
4.4 | 1 ( 0.3) |
| Total | 1.1 (0.7–2.0) |
1462 | 9.2 (5.4–16.0) |
321 | 4.8 (3.6–6.9) |
320 |